Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of R948835 single and multiple ascending doses in healthy volunteers
NL-OMON48536Phase 1Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in autoimmune disease and inflammatory diseases comparing R948835 with Matching placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacodynamic response after LPS challenge. Started Apr 2018; status: active, not recruiting.
02
Drugs
R835
03
Conditions
autoimmune diseaseinflammatory diseases
Beyond the preview
Go deeper on NL-OMON48536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48536.